Drug intelligence / Profile preview

PH733

Development stage: Preclinical
Lead developer: Botamedi
Modality: Small Molecules

Overview

PH733 is a preclinical small molecule drug candidate developed by Botamedi for the treatment of neurodegenerative diseases. It is derived from marine phytochemicals, specifically polyphenols isolated from brown algae using the company's proprietary SEANOL® technology. The drug is characterized by multipotent pharmacological activity and an excellent safety profile. While specific molecular targets have not been disclosed, PH733 is part of a pipeline of marine-derived therapeutics aimed at addressing complex pathologies through natural product-based pharmacology.

Other names: marine phytochemical

Beyond the preview

Go deeper on PH733.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PH733.

Explore the full profile